Cookies on this site

Results of MOSAIC, a European observational study led by researchers at Pandemic Sciences Institute (PSI) and International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), provides evidence on how the clade IIb mpox virus affects patients and the risks of onward transmission.

Mae researcher using a microscope

Clade I and II mpox virus is endemic in Central and West Africa, causing local seasonal outbreaks.  

In May 2022, a new variant of the mpox virus caused the first global outbreak, prompting the World Health Organization (WHO) to declare a Public Health Emergency of International Concern, and causing nearly 90,000 cases worldwide in one year. This variant, known as clade IIb, differs from the mpox typically seen in Africa, particularly in how it spreads and the symptoms it causes.  

With limited available clinical evidence about the disease’s symptoms and best treatments, researchers at PSI and the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) embarked with partners across Europe on a programme of research to generate robust and clinically significant new data.  

Results from one of these studies on a large sample of participants, published in Clinical Infectious Diseases, provide insights into how clade IIb mpox affected people during the recent outbreak, the risks of onwards transmission and health outcomes for patients. 

The observational study – known as MOSAIC and funded by the UK Foreign, Commonwealth and Development Office, Wellcome, the Bill & Melinda Gates Foundation and by the European Commission with the MPX-Response in the European Union – was conducted to better understand the clinical features of mpox and to measure how long it took for lesions to heal and for the virus to clear.   

 

Read the full story on the Nuffield Department of Medicine website.

 

 

Similar stories

Research shows for the first time that standard non-contrast CT scans can be analysed by AI to reveal hidden coronary inflammation

Researchers from 27 institutions across UK, USA, Europe and Australia, led by a team at the University of Oxford, have demonstrated how an AI technology can measure inflammation in the heart’s arteries using low-radiation CT heart scans typically used to measure calcium score.

Five European Research Council (ERC) Synergy Grants awarded to Oxford researchers for ambitious new collaborations

Five Oxford University academics are to co-lead ambitious new research projects backed by European Research Council (ERC) Synergy Grants, part of the EU’s Horizon Europe research and innovation programme. Synergy Grants support groups of two to four outstanding researchers who combine complementary expertise and resources to tackle ambitious scientific challenges that could not be addressed by individual teams alone.

Professor Ole Jensen (Department of Experimental Psychology) and colleagues received €13.6 million to discover when the brain is ready for language and social understanding

The team will use new wearable brain sensors to track cognitive development from before birth to eight years of age.

New 'molecular glue' helps break down antibiotic resistance enzymes in E. coli

Oxford University scientists have discovered a new approach to tackle antimicrobial resistance (AMR), using 'molecular glues' to encourage bacteria to destroy their own resistance-causing enzymes. The study has been published in Angewandte Chemie International Edition.

Stronger immune system may help protect against prostate cancer

Higher levels of proteins involved in activating and coordinating the immune system were associated with a lower risk of developing prostate cancer, in a new study led by researchers at the Nuffield Department of Population Health.

The Nuffield Department of Women's & Reproductive Health has published its Biennial Report 2024–26

The Biennial Report 2024–26 highlights two years of research excellence, innovation, collaboration and growth.